ClinicalTrials.gg
Not yet recruitingNCT07887490Updated Oct 21, 2026

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Anfibatide Injection in Healthy Volunteers

A Phase 1 interventional study of Recombinant Anfibatide Injection and Placebo in Healthy Volunteers, sponsored by Lee's Pharmaceutical Limited. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Lee's Pharmaceutical Limited · Phase 1, Interventional, and Treatment

Updated Oct 21, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a Phase I, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Anfibatide Injection in healthy adult volunteers.

Approximately 36 healthy participants will receive a single intravenous dose of either study drug or matching placebo across sequential dose cohorts. Safety, tolerability, and pharmacokinetic parameters will be assessed following administration.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Lee's Pharmaceutical Limited is the lead sponsor of 74 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female participants aged 18-45 years;
  • Body weight: = weight (kg)/height² (m²) within 19.0-26.0 (inclusive), and body weight ≥50 kg;
  • Participants are in generally good health without a history of significant disease, with normal findings on physical examination, vital signs, 12-lead , and laboratory tests. If abnormal, the clinical judgment that the findings are clinically insignificant permits participation in the clinical trial;
  • Participants volunteer to participate and sign the form;
  • Participants of have no plans for pregnancy, sperm donation, or egg donation from two weeks before screening of this study until 6 months after the end of the trial, and voluntarily take appropriate measures.

Exclusion criteria

Exclusion Criteria:

  • Any medical history or disease
  • Conditions that may increase bleeding risk (e.g., bleeding disorders, recent surgery, abnormal coagulation parameters)
  • History of hypertension, syncope, or convulsions
  • , , , or syphilis infection
  • Drug or alcohol abuse
  • Recent participation in another clinical trial or blood donation
  • Pregnancy or breastfeeding
  • to study drug components
  • Use of any medications within 14 days prior to dosing
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Recombinant Anfibatide Injection

    Recombinant Anfibatide Injection, single intravenous dose.

    Drug: Recombinant Anfibatide Injection

  • Placebo comparator
    Placebo

    Matching placebo injection

    Other: Placebo

Interventions

  • DrugRecombinant Anfibatide Injection

    Recombinant Anfibatide Injection is a polypeptide antithrombotic agent. Administered as a single intravenous bolus injection over approximately 5 minutes.

  • OtherPlacebo

    Matching placebo injection

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)

    Safety and tolerability assessed by the incidence, severity, and relationship of adverse events, graded per NCI CTCAE v6.0, including abnormal laboratory values, vital signs, ECG, and physical examination findings.

    Time frame: From dosing through Day 8 follow-up visit

Secondary outcomes

  1. Time to Maximum Observed Concentration (Tmax) of Recombinant Anfibatide

    Time from dosing to reach the peak concentration of recombinant anfibatide, measured at scheduled time points.

    Time frame: Pre-dose through 48 hours post-dose

  2. Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-t)

    Area under the concentration-time curve of recombinant anfibatide from time zero to the last quantifiable concentration, based on scheduled post-dose measurements.

    Time frame: Pre-dose through 48 hours post-dose

  3. Maximum Observed Concentration (Cmax) of Recombinant Anfibatide

    Peak concentration of recombinant anfibatide following single intravenous administration, measured at scheduled time points.

    Time frame: Pre-dose through 48 hours post-dose

  4. Platelet Aggregation Inhibition Rate (Ristocetin-induced)

    Inhibition rate of ristocetin-induced platelet aggregation measured at scheduled time points after single dose administration.

    Time frame: Pre-dose through 48 hours post-dose

  5. Glycoprotein Ib (GP-Ib) Receptor Binding Rate

    GP-Ib receptor binding rate measured at scheduled time points after single dose administration.

    Time frame: Pre-dose through 48 hours post-dose

  6. Number of Participants With Positive Anti-drug Antibody (ADA)

    Number of participants who tested positive for anti-drug antibody after single dose administration.

    Time frame: Pre-dose and Day 8 post-dose

  7. Number of Participants With Positive Neutralizing Antibody (Nab)

    Number of participants who tested positive for neutralizing antibody after single dose administration.

    Time frame: Pre-dose and Day 8 post-dose

  8. Cumulative Urinary Excretion Amount of Recombinant Anfibatide

    Total amount of recombinant anfibatide recovered in urine over scheduled collection intervals.

    Time frame: Pre-dose through 48 hours post-dose

  9. Cumulative Urinary Excretion Percentage of Recombinant Anfibatide

    Percentage of the administered dose recovered in urine over scheduled collection intervals.

    Time frame: Pre-dose through 48 hours post-dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2026
First posted
Oct 21, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Feb 15, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07887490
Responsible party
Sponsor
First posted
Oct 21, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Feb 15, 2028 (estimated)
Last update
Oct 21, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion